LncRNAs Link Cancer Stemness to Therapy Resistance

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2021 May 5

PMID 33948345

Citations 9

Authors

Jing Yue

Yueguang Wu

Liqing Qiu

Ruping Zhao

Mingfeng Jiang

Hongfang Zhang

Affiliations

Soon will be listed here.

Abstract

Cancer stem cells (CSCs) are a cellular subpopulation accelerating cancer cell growth, invasion and metastasis and survival. After chemoradiotherapy, CSCs are enriched because of their survival advantages and lead to tumor relapse and metastasis. Elimination of CSCs is critically important for the radical treatment of human cancers. Long non-coding RNAs (lncRNAs) are a group of RNAs longer than 200 nucleotides and have no protein-coding potential. Aberrant expressions of lncRNAs are associated with human diseases including cancer. LncRNAs function as cancer biomarkers, prognostic factors and therapeutic targets. They induce cancer stemness by chromatin modification, transcriptional regulation or post-transcriptional regulation of target genes as a sponge or through assembling a scaffold complex. Several factors caused aberrant expressions of lncRNAs in CSCs such as genes mutations, epigenetic alteration and environmental stimuli. Targeting of lncRNAs has been demonstrated to significantly reverse the chemoradioresistance of CSCs. In this review, we have summarized the progress of studies regarding lncRNAs-mediated therapy resistance of CSCs and clarified the molecular mechanisms. Furthermore, we have for the first time analyzed the influences of lncRNAs on cell metabolism and emphasized the effect of tumor microenvironment on lncRNAs functions in CSCs. Overall, the thorough understanding of the association of lncRNAs and CSCs would contribute to the reversal of therapy resistance.

Citing Articles

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

N6-methyladenosine-modified long non-coding RNA promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression.

Yu Y, Lu X, Mu J, Meng J, Sun J, Chen H World J Gastroenterol. 2024; 30(48):5174-5190.

PMID: 39735272 PMC: 11612700. DOI: 10.3748/wjg.v30.i48.5174.

LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance.

Elimam H, Moussa R, Radwan A, Hatawsh A, Elfar N, Alhamshry N Funct Integr Genomics. 2024; 24(5):175.

PMID: 39325107 DOI: 10.1007/s10142-024-01450-8.

LncRNA CECR7 boosts hepatocellular carcinoma progression by recruiting RNA binding protein U2AF2 to enhance the stability of EXO1 mRNA.

Zhao L, Zang Q, Liang G, Yao X Heliyon. 2023; 9(9):e19862.

PMID: 37809785 PMC: 10559240. DOI: 10.1016/j.heliyon.2023.e19862.

Clinical implications of lncRNA LINC-PINT in cancer.

Bukhari I, Khan M, Li F, Swiatczak B, Thorne R, Zheng P Front Mol Biosci. 2023; 10:1097694.

PMID: 37006616 PMC: 10064087. DOI: 10.3389/fmolb.2023.1097694.

References

Huang G, Wang M, Li X, Wu J, Chen S, Du N . TUSC7 suppression of Notch activation through sponging MiR-146 recapitulated the asymmetric cell division in lung adenocarcinoma stem cells. Life Sci. 2019; 232:116630. DOI: 10.1016/j.lfs.2019.116630. View

Zhang H, Hua Y, Jiang Z, Yue J, Shi M, Zhen X . Cancer-associated Fibroblast-promoted LncRNA Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2018; 25(6):1989-2000. DOI: 10.1158/1078-0432.CCR-18-0773. View

Kahn M . Can we safely target the WNT pathway?. Nat Rev Drug Discov. 2014; 13(7):513-32. PMC: 4426976. DOI: 10.1038/nrd4233. View

Di Cecilia S, Zhang F, Sancho A, Li S, Aguilo F, Sun Y . RBM5-AS1 Is Critical for Self-Renewal of Colon Cancer Stem-like Cells. Cancer Res. 2016; 76(19):5615-5627. PMC: 5050123. DOI: 10.1158/0008-5472.CAN-15-1824. View

Mazor G, Levin L, Picard D, Ahmadov U, Caren H, Borkhardt A . The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis. 2019; 10(3):246. PMC: 6416247. DOI: 10.1038/s41419-019-1477-5. View

Lan T, Yuan K, Yan X, Xu L, Liao H, Hao X . LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop. Cancer Res. 2019; 79(13):3220-3234. DOI: 10.1158/0008-5472.CAN-18-4044. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Chen X, Xie R, Gu P, Huang M, Han J, Dong W . Long Noncoding RNA Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. Clin Cancer Res. 2018; 25(4):1389-1403. DOI: 10.1158/1078-0432.CCR-18-1656. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

10.

Wang M, Li Y, Xiao G, Zheng X, Wang J, Xu C . H19 regulation of oestrogen induction of symmetric division is achieved by antagonizing Let-7c in breast cancer stem-like cells. Cell Prolif. 2018; 52(1):e12534. PMC: 6430450. DOI: 10.1111/cpr.12534. View

11.

Zhou T, Wu L, Ma N, Tang F, Yu Z, Jiang Z . SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9. Cell Death Dis. 2020; 11(12):1071. PMC: 7736271. DOI: 10.1038/s41419-020-03273-4. View

12.

Xu C, Xiao G, Zhang B, Wang M, Wang J, Liu D . CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade. Gene Ther. 2018; 25(1):4-12. DOI: 10.1038/gt.2017.98. View

13.

Borst P . Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biol. 2012; 2(5):120066. PMC: 3376736. DOI: 10.1098/rsob.120066. View

14.

Zhou H, Xiong Y, Peng L, Wang R, Zhang H, Fu Z . LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. J Cell Biochem. 2019; 121(3):2510-2524. DOI: 10.1002/jcb.29473. View

15.

Kim S, Harford J, Moghe M, Rait A, Pirollo K, Chang E . Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2017; 46(3):1424-1440. PMC: 5815062. DOI: 10.1093/nar/gkx1221. View

16.

Soares J, Soares A, Rodrigues V, Melendez M, Santos A, Faria E . Detection of the Prostate Cancer Biomarker PCA3 with Electrochemical and Impedance-Based Biosensors. ACS Appl Mater Interfaces. 2019; 11(50):46645-46650. DOI: 10.1021/acsami.9b19180. View

17.

Yang C, Cai W, Dong Z, Guo J, Zhao Y, Sui C . lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene. 2018; 687:73-81. DOI: 10.1016/j.gene.2018.10.087. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Reifenberger G, Wirsching H, Knobbe-Thomsen C, Weller M . Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2016; 14(7):434-452. DOI: 10.1038/nrclinonc.2016.204. View

20.

Zhang R, Tang T, Yu H, Yao X . LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling. Biochem Biophys Res Commun. 2018; 507(1-4):260-266. DOI: 10.1016/j.bbrc.2018.11.019. View